The Moving Average Convergence Divergence (MACD) for FMED turned positive on November 09, 2026. Looking at past instances where FMED's MACD turned positive, the stock continued to rise in 29 of 33 cases over the following month. The odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on FMED as a result. In 49 of 59 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
FMED moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for FMED crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where FMED advanced for three days, in 171 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 124 of 143 cases where FMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
FMED broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
KROS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend. In 39 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KROS's RSI Indicator exited the oversold zone, 29 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on KROS as a result. In 75 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for KROS just turned positive on November 17, 2026. Looking at past instances where KROS's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
Following a +19.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 224 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
KROS broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KROS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.596). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
KROS | ||
|---|---|---|
OUTLOOK RATING 1..100 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 95 | |
PRICE GROWTH RATING 1..100 | 56 | |
P/E GROWTH RATING 1..100 | 98 | |
SEASONALITY SCORE 1..100 | 27 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| FMED | KROS | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 78% |
| Stochastic ODDS (%) | 2 days ago 73% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 72% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 77% |
| Advances ODDS (%) | 12 days ago 84% | 4 days ago 76% |
| Declines ODDS (%) | 10 days ago 83% | 2 days ago 75% |
| BollingerBands ODDS (%) | 2 days ago 78% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 79% |
A.I.dvisor indicates that over the last year, FMED has been loosely correlated with BNTX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if FMED jumps, then BNTX could also see price increases.
| Ticker / NAME | Correlation To FMED | 1D Price Change % | ||
|---|---|---|---|---|
| FMED | 100% | N/A | ||
| BNTX - FMED | 49% Loosely correlated | -0.52% | ||
| VRTX - FMED | 47% Loosely correlated | -1.08% | ||
| IMVT - FMED | 46% Loosely correlated | -2.31% | ||
| DYN - FMED | 46% Loosely correlated | -3.31% | ||
| KROS - FMED | 45% Loosely correlated | -2.72% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| HDLB | 16.01 | 0.07 | +0.43% |
| ETRACS Monthly Pay 2xLeveraged US High Dividend Low Volatility ETN Series B (HDLB) | |||
| DURA | 38.93 | -0.23 | -0.59% |
| VanEck Durable High Dividend ETF (DURA) | |||
| DJUL | 48.56 | -1.03 | -2.07% |
| FT Vest U.S. Equity Deep Buffer ETF - July (DJUL) | |||
| MFEM | 22.49 | -1.23 | -5.18% |
| PIMCO RAFI Dynamic Multi-Factor Emerging Markets Equity ETF (MFEM) | |||
| ARTY | 53.94 | -5.50 | -9.25% |
| iShares Future AI & Tech ETF (ARTY) | |||